Serum CD44 in non-Hodgkin's lymphoma

Leukemia and Lymphoma

Volumn 33, Issue 5-6, 1999, Pages 433-440

  Ristamäki, Raija ^a,b   Joensuu, Heikki ^c   Jalkanen, Sirpa ^b  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

^b NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Adhesion molecule; CD44; Non Hodgkin's lymphoma; Prognosis; Survival

Indexed keywords

CELL ADHESION MOLECULE; HERMES ANTIGEN; MEMBRANE ANTIGEN;

ANTIGEN EXPRESSION; BLOOD LEVEL; CANCER GROWTH; HUMAN; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; REVIEW;

EID: 2542509718     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428199909058448     Document Type: Review

References (53)

1. Goodfellow, P. N., Banting, G., Wiles, M. V., Tunnacliffe, A., Parkar, M., Solomon, E., Dalchau, R. and Fabre, J. W. (1982). The gene, MIC4, which controls expression of the antigen defined by monoclonal antibody F10.44.2, is on human chromosome 11. Eur. J. Immunol., 12, 659-663.
2. Screaton, G. R., Bell, M. V., Jackson, D. G., Cornelis, F. B., Gerth, U. and Bell, J. I. (1992). Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons. Proc. Natl. Acad. Sci. USA, 89, 12160-12164.
3. Jalkanen, S., Jalkanen, M., Bargatze, R., Tammi, M. and Butcher, E. C. (1988). Biochemical properties of glycoproteins involved in lymphocyte recognition of high endothelial venules in man. J. Immunol., 141, 1615-1623.
4. Brown, T. A., Bouchard, T., St.John, T., Wayner, E. and Carter, W. G. (1991). Human keratinocytes express a new CD44 core protein (CD44E) as a heparan-sulfate intrinsic membrane proteoglycan with additional exons. J. Cell Biol., 113, 207-221.
5. Jackson, D. G., Bell, J. I., Dickinson, R., Timans, J., Shields, J. and Whittle, N. (1995). Proteoglycan forms of the lymphocyte homing receptor CD44 are alternatively spliced variants containing the v3 exon. J. Cell Biol., 128, 673-685.
6. Zhou, D. F., Ding, J. F., Picker, L. J., Bargatze, R. F., Butcher, E. C. and Goeddel, D. V. (1989). Molecular cloning and expression of Pgp-1. The mouse homolog of the human H-CAM (Hermes) lymphocyte homing receptor. J. Immunol., 143, 3390-3395.
7. Jalkanen, S. T., Bargatze, R. F., Herron, L. R. and Butcher, E. C. (1986). A lymphoid cell surface glycoprotein involved in endothelial cell recognition and lymphocyte homing in man. Eur. J. Immunol., 16, 1195-1202.
8. Picker, L. J., Nakache, M. and Butcher, E. C. (1989). Monoclonal antibodies to human lymphocyte homing receptors define a novel class of adhesion molecules on diverse cell types. J. Cell Biol., 109, 927-937.
9. Shimizu, Y., Van Seventer, G. A., Siraganian, R., Wahl, L. and Shaw, S. (1989). Dual role ofthe CD44 molecule in T cell adhesion and activation. J. Immunol., 143, 2457-2463.
10. Haynes, B. F., Telen, M. J., Hale, L. P. and Denning, S. M. (1989). CD44-a molecule involved in leukocyte adherence and T-cell activation [published erratum appears in Immunol Today 1990 Mar; 11 (3):80]. Immunol. Today, 10, 423-428.
11. Miyake, K., Medina, K. L., Hayashi, S., Ono, S., Hamaoka, T. and Kincade, P. W. (1990). Monoclonal antibodies to Pgp-1/CD44 block lympno-hemopoiesis in long-term bone marrow cultures. J. Exp. Med., 171, 477-488.
12. Koopman, G., van Kooyk, Y., de Graaff, M., Meyer, C. J., Figdor, C. G. and Pals, S. T. (1990). Triggering of the CD44 antigen on T lymphocytes promotes T cell adhesion through the LFA-1 pathway. J. Immunol., 145, 3589-3593.
13. Bennett, K. L., Jackson, D. G., Simon, J. C., Tanczos, E., Peach, R., Modrell, B., Stamenkovic, I., Plowman, G. and Aruffo, A. (1995). CD44 isoforms containing exon V3 are responsible for the presentation of heparin-binding growth factor. J. Cell Biol., 128, 687-698.
14. Yu, Q., Toole, B. P. and Stamenkovic, I. (1997). Induction of apoptosis of metastatic mammary carcinoma cells in vivo by disruption of tumor cell surface CD44 function. J. Exp. Med., 186, 1985-1996.
15. Aruffo, A., Stamenkovic, I., Melnick, M., Underhill, C. B. and Seed, B. (1990). CD44 is the principal cell surface receptor for hyaluronate. Cell, 61, 1303-1313.
16. Underhill, C. (1992). CD44: the hyaluronan receptor. J. Cell Sci., 103, 293-298.
17. Stamenkovic, I., Aruffo, A., Amiot, M. and Seed, B. (1991). The hematopoietic and epithelial forms of CD44 are distinct polypeptides with different adhesion potentials for hyaluronate-bearing cells. EMBO J., 10, 343-348.
18. Perschl, A., Lesley, J., English, N., Trowbridge, I. and Hyman, R. (1995). Role of CD44 cytoplasmic domain in hyaluronan binding. Eur. J. Immunol., 25, 495-501.
19. Lesley, J., English, N., Perschl, A., Gregoroff, J. and Hyman, R. (1995). Variant cell lines selected for alterations in the function of the hyaluronan receptor CD44 show differences in glycosylalion. J. Exp. Med., 182, 431-437.
20. Katoh, S., Zheng, Z., Oritani, K., Shimozato, T. and Kincade, P. W. (1995). Glycosylation of CD44 negatively regulates its recognition of hyaluronan. J. Exp. Med., 182, 419-429.
21. Jalkanen, S. and Jalkanen, M. (1992). Lymphocyte CD44 binds the COOH-terminal heparin-binding domain of fibronectin. J. Cell Biol., 116, 817-825.
22. Wayner, E. A. and Carter, W.G. (1987). Identification of multiple cell adhesion receptors for collagen and fibronectin in human fibrosarcoma cells possessing unique alpha and common beta subunits. J. Cell Biol., 105, 1873-1884.
23. Carter, W. G. and Wayner, E. A. (1988). Characterization of the class III collagen receptor, a phosphorylated, transmembrane glycoprotein expressed in nucleated human cells. J. Biol. Chem., 263, 4193-4201.
24. Toyama Sorimachi, N., Sorimachi, H., Tobita, Y., Kitamura, F., Yagita, H., Suzuki, K. and Miyasaka, M. (1995). A novel ligand for CD44 is serglycin, a hematopoietic cell lineage-specific proteoglycan. Possible involvement in lymphoid cell adherence and activation. J. Biol. Chem., 270, 7437-7444.
25. Weber, G. F., Ashkar, S., Glimcher, M. J. and Cantor, H. (1996). Receptor-ligand interaction between CD44 and osteopontin (Eta-1). Science, 271, 509-512.
26. Naujokas, M. F., Morin, M., Anderson, M. S., Peterson, M. and Miller, J. (1993). The chondroitin sulfate form of invariant chain can enhance stimulation of T cell responses through interaction with CD44. Cell. 74, 257-268.
27. Horst, E., Meijer, C. J., Radaszkiewicz, T., Ossekoppele, G. J., Van Krieken, J. H. and Pals, S. T. (1990). Adhesion molecules in the prognosis of diffuse large-cell lymphoma: expression of a lymphocyte homing receptor (CD44), LFA-1 (CD11a/18), and ICAM-1 (CD54). Leukemia. 4, 595-599.
28. Jalkanen, S., Joensuu, H., Soderstrom, K. O. and Klemi, P. (1991). Lymphocyte homing and clinical behavior of non-Hodgkin's lymphoma. J. Clin. Invest., 87, 1835-1840.
29. Guo, Y., Ma, J., Wang, J., Che, X., Narula, J., Bigby, M., Wu, M. and Sy, M. S. (1994). Inhibition of human melanoma growth and metastasis in vivo by anti-CD44 monoclonal antibody [published erratum appears in Cancer Res 1994 Apr 15;54(8):2284]. Cancer Res., 54, 1561-1565.
30. Sy, M. S., Guo, Y. J. and Stamenkovic, I. (1992). Inhibition oftumor growth in vivo with a soluble CD44-immunoglobulin fusion protein. J. Exp. Med., 176, 623-627.
31. Gunthert, U., Hofmann, M., Rudy, W., Reber, S., Zoller, M., Haussmann, I., Matzku, S., Wenzel, A., Ponta, H. and Herrlich, P. (1991). A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell, 65, 13-24.
32. Dalchau, R., Kirkley, J. and Fahre, J. W. (1980). Monoclonal antibody to a human brain-granulocyte-T lymphocyte antigen probably homologous to the W 3/13 antigen of the rat. Eur. J. Immunol., 10, 745-749.
33. Telen, M. J., Eisenbarth, G. S. and Haynes, B. F. (1983). Human erythrocyte antigens. Regulation of expression of a novel erythrocyte surface antigen by the inhibitor Lutheran In(Lu) gene. J. Clin. Invest., 71, 1878-1886.
34. Lucas, M. G., Green, A. M. and Telen, M. J. (1989). Characterization ofthe serum In(Lu)-related antigen: identification of a serum protein related to erythrocyte p80. Blood, 73, 596-600.
35. Haynes, B. F., Hale, L. P., Patton, K. L., Martin, M. E. and McCallum, R. M. (1991). Measurement of an adhesion molecule as an indicator of inflammatory disease activity. Up-regulation of the receptor for hyaluronate (CD44) in rheumatoid arthritis. Arthritis. Rheum., 34, 1434-1443.
36. Katoh, S., McCarthy, J. B. and Kincade, P. W. (1994). Characterization of soluble CD44 in the circulation of mice. Levels are affected by immune activity and tumor growth J. Immunol., 153, 3440-3449.
37. Bazil, V. and Horejsi, V. (1992). Shedding of the CD44 adhesion molecule from leukocytes induced by anti-CD44 monoclonal antibody simulating the effect of a natural receptor ligand. J. Immunol., 149, 747-753.
38. Camp, R. L., Scheynius, A., Johansson, C. and Pure, E. (1993). CD44 is necessary for optimal contact allergic responses but is not required for normal leukocyte extravasation. J. Exp. Med., 178, 497-507.
39. Campanero, M. R., Pulido, R., Alonso, J. L., Pivel, J. P., Pimentel Muinos, F. X., Fresno, M. and Sanchez Madrid, F. (1991). Down-regulation by tumor necrosis factor-alpha of neutrophil cell surface expression of the sialophorin CD43 and the hyaluronate receptor CD44 through a proteolytic mechanism. Eur. J. Immunol., 21, 3045-3048.
40. Bazil, V. and Strominger, J. L. (1994). Metalloprotease and serine protease are involved in cleavage of CD43, CD44, and CD16 from stimulated human granulocytes. Induction of cleavage of L-selectin via CD16. J. Immunol., 152, 1314-1322.
41. Guo, Y. J., Liu, G., Wang, X., Jin, D., Wu, M., Ma, J. and Sy, M. S. (1994). Potential use of soluble CD44 in serum as indicator of tumor burden and metastasis in patients with gastric or colon cancer. Cancer Res., 54, 422-426.
42. Martin, S., Jansen, F., Bokelmann, J. and Kolb, H. (1997). Soluble CD44 splice variants in metastasizing human breast cancer. Int. J. Cancer, 74, 443-445.
43. Kittl, E. M., Ruckser, R., Selleny, S., Samek, V., Hofmann, J., Huber, K., Reiner, A., Ogris, E., Hinterberger, W. and Bauer, K. (1997). Evaluation of soluble CD44 splice variant v5 in the diagnosis and follow-up in breast cancer patients. Exp. Clin. Immunogenet., 14, 264-272.
44. Gadducci, A., Ferdeghini, M., Fanucchi, A., Annicchiarico, C., Cosio, S., Prontera, C., Bianchi, R. and Genazzani, A. R. (1997). Serum assay of soluble CD44 standard (sCD44-st), CD44 splice variant v5 (sCD44-v5), and CD44 splice variant v6 (sCD44-v6) in patients with epithelial ovarian cancer. Anticancer Res., 17, 4463-4466.
45. Zeimet, A. G., Widschwendter, M., Uhl Steidl, M., Muller Holzner, E., Daxenbichler, G., Marth, C. and Dapunt, O. (1997). High serum levels of soluble CD44 variant isoform v5 are associated with favourable clinical outcome in ovarian cancer. Br. J. Cancer, 76, 1646-1651.
46. De Rossi, G., Marroni, P., Paganuzzi, M., Mauro, F. R., Tenca, C., Zarcone, D., Velardi, A., Molica, S. and Grossi, C. E. (1997). Increased serum levels of soluble CD44 standard, but not of variant isoforms v5 and v6, in B cell chronic lymphocytic leukemia. Leukemia, 11, 134-141.
47. Ristamäki, R., Joensuu, H., Grön-Virta, K., Salmi, M. and Jalkanen, S. (1997). Origin and function of circulating CD44 in non-Hodkgin's lymphoma. J. Immunol., 158, 3000-3008.
48. Clayberger, C., Wright, A., Medeiros, L. J., Koller, T. D., Link, M. P., Smith, S. D., Warnke, R. A. and Krensky, A. M. (1987). Absence of cell surface LFA-1 as a mechanism of escape from immunosurveillance. Lancet. 2, 533-536.
49. Ristamäki, R., Joensuu, H., Salmi, M. and Jalkanen, S. (1994). Serum CD44 in malignant lymphoma: an association with treatment response. Blood, 84, 238-243.
50. Ristamäki, R., Joensuu, H., Hagberg, H., Kälkner, K. M. and S., J. (1998). Clinical significance of circulating CD44 in non-Hodgkin's lymphoma. Int. J. Cancer, 79, 221-225.
51. Ristamaki, R., Joensuu, H., Lappalainen, K., Teerenhovi, L. and Jalkanen, S. (1997). Elevated serum CD44 level is associated with unfavorable outcome in non-Hodgkin's lymphoma. Blood, 90, 4039-4045.
52. Kittl, E. M., Ruckser, R., Rech-Weichselbraun, I., Hinterberger, W. and Bauer, K. (1997). Significant elevation of tumour-associated isoforms of soluble CD44 in serum of normal individuals caused by cigarette smoking. Eur. J. Clin. Chem. Clin. Biochem., 35, 81-84.
53. Guo, Y. J., Liu, G., Wang, X., Jin, D., Wu, M., Ma, J. and Sy, M. S. (1994). Potential use of soluble CD44 in serum as indicator of tumor burden and metastasis in patients with gastric or colon cancer. Cancer Res., 54, 422-426.